Close Menu

GenMark

The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.

The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.

The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.

The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.

GenMark got clearance for an assay to detect fungal pathogens from blood cultures of patients with suspected bloodstream infections, and it received clearance for a bacterial assay.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.

Pages